afatinib
afatinib brief description
cas no.:850140-72-6
mf:c24h25clfn5o3
mw:485.9384032
competitive price with high quality
conforms to bp/usp/ep/fcc
afatinib coa
item | standard | results |
appearance | off-white powder | off-white powder |
identification | hplc ,nmr | complies |
residue on ignition | ≤0.10% | 0.05% |
loss on drying | ≤0.50% | 0.15% |
heavy metal | ≤20ppm | <20ppm |
purity(hplc) | ≥99.0% | 99.99% |
conclusion | it complies with enterprise standard |
medical use
afatit has received regulatory approval for use as a treatment for non-small cell lung cancer,although there is emerging evidence to support its use in other cancers such as breast cancer.
in october 2010 a phase iii trial in nsclc patients called lux-lung 5 began with this drug.fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.in may 2012, the phase iib/iii trial lux-lung 1 came to the same conclusion.
in january 2015 a phase iii trial in people with nsclc suggested the drug extended life expactancy in stage iv nsclc adenocarcinoma with egfr mutation type del 19-positive tumors, compared to cisplatin-based chemotherapy by a year (33 months vs. 21 months).
phase ii results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib.[9] double-blind phase iii trials are under way to confirm or refute this finding. her2-negative breast cancers showed limited or no response to the drug.
Afghanistan
